Akums Drugs to Establish Manufacturing Facility in Zambia, Reports Q2 Results
Akums Drugs and Pharmaceuticals Limited announced a joint venture with the Zambian government to establish a local manufacturing facility, holding a 51% stake. The facility, set for completion by 2028, will produce various pharmaceutical products and serve as an export base for Southern African countries. The Zambian government committed to purchase $50 million worth of medicines from Akums' Indian facilities. Simultaneously, Akums reported a 5.50% increase in net profit to ₹63.48 crore and a 0.48% rise in sales to ₹1024.03 crore in its latest quarterly results. The company's stock experienced a slight decline of 0.19%, trading at ₹480.90.
*this image is generated using AI for illustrative purposes only.
Akums Drugs and Pharmaceuticals Limited has announced a significant international expansion move, coupled with the release of its latest quarterly results. The pharmaceutical company is set to establish a local manufacturing facility in Zambia through a strategic joint venture, while also reporting a rise in profits for the most recent quarter.
Zambian Joint Venture
Akums Drugs has entered into an agreement with the Government of Zambia to set up a local manufacturing facility. The joint venture will see Akums holding a 51% majority stake, with the Zambian government owning the remaining 49%. This partnership marks a significant step in the company's international expansion strategy.
Key points of the joint venture include:
- The facility is expected to be completed by 2028.
- It will manufacture a range of pharmaceutical products including general oral solids, liquids, injectables, and beta-lactam products.
- The Zambian government has committed to purchase medicines worth $50 million from Akums' facilities in India over the period 2026-2027.
- Akums plans to use the Zambian facility as a base to export to neighboring Southern African countries, including Botswana, Malawi, Mozambique, Namibia, Tanzania, and Zimbabwe.
This move is likely to strengthen Akums' presence in the African pharmaceutical market and potentially open up new revenue streams for the company.
Quarterly Financial Results
Alongside the announcement of its Zambian venture, Akums Drugs and Pharmaceuticals also reported its quarterly financial results:
| Financial Metric | Q2 Results | Change |
|---|---|---|
| Net Profit | ₹63.48 crore | Up 5.50% |
| Sales | ₹1024.03 crore | Up 0.48% |
The company has shown a modest improvement in its financial performance, with a 5.50% increase in net profit compared to the previous period. Sales also saw a slight uptick, rising by 0.48% to reach ₹1024.03 crore.
Stock Performance
Following these announcements, Akums Drugs and Pharmaceuticals' shares experienced a marginal decline of 0.19%. The stock is currently trading at ₹480.90.
The combination of international expansion plans and steady financial growth presents a mixed picture for Akums Drugs and Pharmaceuticals. While the Zambian joint venture opens up new opportunities for market expansion in Africa, the modest financial growth and slight dip in share price suggest that investors may be taking a cautious approach to these developments.
20
